H.C. Wainwright Raises its Price Target on Aktis Oncology (AKTS) to $33

1 week ago 8

Jeff Lewis

Sun, April 12, 2026 astatine 4:18 PM CDT 1 min read

Aktis Oncology, Inc. (NASDAQ:AKTS) is 1 of the

8 Healthcare Stocks Insiders Are Buying. On March 31, 2026, H.C. Wainwright expert Robert Burns raised the firm’s terms people connected Aktis Oncology, Inc. (NASDAQ:AKTS) to $33 from $30 antecedently and maintained a Buy standing connected the shares. Robert Burns has said that the company’s pipeline is expected to beforehand and grow implicit the adjacent 12 months.

On March 30, 2026, Aktis Oncology, Inc. (NASDAQ:AKTS) announced the FDA clearance of investigational caller cause applications to statesman a Phase 1b proceedings for AKY-25191, a miniprotein radioconjugate targeting B7-H3 crossed aggregate coagulated tumors, including prostate and lung cancers.

H.C. Wainwright Raises its Price Target connected Aktis Oncology (AKTS) to $33

Aktis Oncology, Inc. (NASDAQ:AKTS) said that AKY-2519 is its 2nd clinical-stage miniprotein radioconjugate, portion its pb program, AKY-1189, targeting Nectin-4, is already enrolling successful a Phase 1b study, with some designed to present actinium-225 to tumor sites.

Aktis Oncology, Inc. (NASDAQ:AKTS) develops radiopharmaceutical therapies for coagulated tumors.

While we admit the imaginable of AKTS arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey connected Google News.

Read Entire Article